EP Patent

EP3650027A1 — Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin

Assigned to Sage Therapeutics Inc · Expires 2020-05-13 · 6y expired

What this patent protects

Formulations of comprising the neuroactive steroid allopregnanolone, and a cyclodextrin, e.g., a β-cyclodextrin, preferably a sulfo butyl ether β-cyclodextrin, e.g., CAPTISOL®; and use thereof in treating CNS disorders.

USPTO Abstract

Formulations of comprising the neuroactive steroid allopregnanolone, and a cyclodextrin, e.g., a β-cyclodextrin, preferably a sulfo butyl ether β-cyclodextrin, e.g., CAPTISOL®; and use thereof in treating CNS disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3650027A1
Jurisdiction
EP
Classification
—
Expires
2020-05-13
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.